caa a22 4500 606174745 CHVBK 20210128100739.0 cr unu---uuuuu 210128e20150801xx s 000 0 eng 10.1007/s00018-015-1918-y doi (NATIONALLICENCE)springer-10.1007/s00018-015-1918-y Bone microenvironment signals in osteosarcoma development [Elektronische Daten] [Arantzazu Alfranca, Lucia Martinez-Cruzado, Juan Tornin, Ander Abarrategi, Teresa Amaral, Enrique de Alava, Pablo Menendez, Javier Garcia-Castro, Rene Rodriguez] The bone is a complex connective tissue composed of many different cell types such as osteoblasts, osteoclasts, chondrocytes, mesenchymal stem/progenitor cells, hematopoietic cells and endothelial cells, among others. The interaction between them is finely balanced through the processes of bone formation and bone remodeling, which regulates the production and biological activity of many soluble factors and extracellular matrix components needed to maintain the bone homeostasis in terms of cell proliferation, differentiation and apoptosis. Osteosarcoma (OS) emerges in this complex environment as a result of poorly defined oncogenic events arising in osteogenic lineage precursors. Increasing evidence supports that similar to normal development, the bone microenvironment (BME) underlies OS initiation and progression. Here, we recapitulate the physiological processes that regulate bone homeostasis and review the current knowledge about how OS cells and BME communicate and interact, describing how these interactions affect OS cell growth, metastasis, cancer stem cell fate and therapy outcome. Springer Basel, 2015 Bone sarcoma nationallicence Growth plate nationallicence Osteoblast nationallicence Osteoclast nationallicence Tumor stroma nationallicence Microenvironment signaling nationallicence Mesenchymal stem cell nationallicence MicroRNA nationallicence AKT : V-Akt murine thymoma viral oncogene homolog nationallicence ALDH : Aldehyde dehydrogenase nationallicence BM : Bone marrow nationallicence BMP : Bone morphogenic proteins nationallicence CCL : Chemokine (C-C Motif) ligands nationallicence CSC : Cancer stem cells nationallicence CXCL : Chemokine (C-X-C Motif) ligands nationallicence DKK : Dickkopf proteins nationallicence ECM : Extracellular matrix nationallicence EDN1 : Endothelin 1 nationallicence EMV : Extracellular membrane vesicles nationallicence EPH : Erythropoietin-producing hepatoma nationallicence ERK : Extracellular signal-related kinases nationallicence FGF : Fibroblast growth factors nationallicence GLI : Glioma-associated oncogene nationallicence GH : Growth hormone nationallicence GP : Growth plate nationallicence HES : Hairy and enhancer of split nationallicence HH : Hedgehog proteins nationallicence HIF : Hypoxia-inducible factors nationallicence IGF : Insulin-like growth factors nationallicence IHH : Indian hedgehog nationallicence IL : Interleukin nationallicence MAPK : Mitogen-activated protein kinases nationallicence MCT : Monocarboxylate transporter nationallicence miRs : MicroRNAs nationallicence MMP : Matrix metalloproteinases nationallicence MSC : Mesenchymal stem/progenitor cells nationallicence mTOR : Mammalian target of rapamycin nationallicence NFkB : Nuclear factor kB nationallicence OPG : Osteoprotegerin nationallicence OS : Osteosarcoma nationallicence PDGF : Platelet-derived growth factor nationallicence PI3K : Phosphatidylinositol-4,5-bisphosphate 3-kinase nationallicence PTHrP : Parathyroid hormone-related peptide nationallicence RANK : Receptor activator of nuclear factor kappa B nationallicence RANKL : RANK ligand nationallicence RB : Retinoblastoma nationallicence SOX2 : Sex-determining region Y-box 2 nationallicence STAT3 : Signal transducer and activator of transcription 3 nationallicence TGFα/β : Transforming growth factor α/β nationallicence VEGF : Vascular endothelial growth factors nationallicence WIF1 : WNT inhibitory factor 1 nationallicence WNT : Wingless-type MMTV integration site family nationallicence YAP1 : Yes-associated protein 1 nationallicence Alfranca Arantzazu Unidad de Biotecnología Celular, Área de Genética Humana, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain aut Martinez-Cruzado Lucia Hospital Universitario Central de Asturias and Instituto Universitario de Oncología del Principado de Asturias, 33006, Oviedo, Spain aut Tornin Juan Hospital Universitario Central de Asturias and Instituto Universitario de Oncología del Principado de Asturias, 33006, Oviedo, Spain aut Abarrategi Ander Unidad de Biotecnología Celular, Área de Genética Humana, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain aut Amaral Teresa Molecular Pathology Program, Institute of Biomedical Research of Salamanca-Centro de Investigación del Cáncer, Centro de Investigación del Cáncer (IBSAL-CIC), Salamanca, Spain aut de Alava Enrique Molecular Pathology Program, Institute of Biomedical Research of Salamanca-Centro de Investigación del Cáncer, Centro de Investigación del Cáncer (IBSAL-CIC), Salamanca, Spain aut Menendez Pablo Cell Therapy Program, School of Medicine, Josep Carreras Leukemia Research Institute, University of Barcelona, Barcelona, Spain aut Garcia-Castro Javier Unidad de Biotecnología Celular, Área de Genética Humana, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain aut Rodriguez Rene Hospital Universitario Central de Asturias and Instituto Universitario de Oncología del Principado de Asturias, 33006, Oviedo, Spain aut Cellular and Molecular Life Sciences Springer Basel 72/16(2015-08-01), 3097-3113 1420-682X 72:16<3097 2015 72 18 https://doi.org/10.1007/s00018-015-1918-y text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 review-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00018-015-1918-y text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Alfranca Arantzazu Unidad de Biotecnología Celular, Área de Genética Humana, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain aut NATIONALLICENCE 700 1- Martinez-Cruzado Lucia Hospital Universitario Central de Asturias and Instituto Universitario de Oncología del Principado de Asturias, 33006, Oviedo, Spain aut NATIONALLICENCE 700 1- Tornin Juan Hospital Universitario Central de Asturias and Instituto Universitario de Oncología del Principado de Asturias, 33006, Oviedo, Spain aut NATIONALLICENCE 700 1- Abarrategi Ander Unidad de Biotecnología Celular, Área de Genética Humana, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain aut NATIONALLICENCE 700 1- Amaral Teresa Molecular Pathology Program, Institute of Biomedical Research of Salamanca-Centro de Investigación del Cáncer, Centro de Investigación del Cáncer (IBSAL-CIC), Salamanca, Spain aut NATIONALLICENCE 700 1- de Alava Enrique Molecular Pathology Program, Institute of Biomedical Research of Salamanca-Centro de Investigación del Cáncer, Centro de Investigación del Cáncer (IBSAL-CIC), Salamanca, Spain aut NATIONALLICENCE 700 1- Menendez Pablo Cell Therapy Program, School of Medicine, Josep Carreras Leukemia Research Institute, University of Barcelona, Barcelona, Spain aut NATIONALLICENCE 700 1- Garcia-Castro Javier Unidad de Biotecnología Celular, Área de Genética Humana, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain aut NATIONALLICENCE 700 1- Rodriguez Rene Hospital Universitario Central de Asturias and Instituto Universitario de Oncología del Principado de Asturias, 33006, Oviedo, Spain aut NATIONALLICENCE 773 0- Cellular and Molecular Life Sciences Springer Basel 72/16(2015-08-01), 3097-3113 1420-682X 72:16<3097 2015 72 18